Cytomegalovirus Infection

Thomas' Hematopoietic Cell Transplantation: Stem Cell Transplantation, Fourth Edition

Volumn , Issue , 2009, Pages 1367-1381

  Zaia, John A ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

CMV associated disease in HCT allograft recipients in pre antiviral era; CMV associated interstitial pneumonia; Human cytomegalovirus (CMV); Immune response to CMV infection; IVIg for prevention of CMV in HCT; Pre emptive treatment strategy for prevention of CMV after HCT

Indexed keywords

EID: 78649978151     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444303537.ch90     Document Type: Chapter

References (134)

1. Meyers JD, Flournoy N, Thomas ED. Nonbacterial pneumonia after allogeneic marrow transplantation: a review of ten years' experience. Rev Infect Dis 1982; 4: 1119-32.
2. Zaia JA. Prevention of cytomegalovirus disease in hematopoietic stem cell transplantation. Clin Infect Dis 2002; 35: 999-1004.
3. DeMarchi JM, Blankenship ML, Brown GD et al. Size and complexity of human cytomegalovirus DNA. Virology 1978; 89: 643-6.
4. Chee MS, Bankier AT, Beck S et al. Analysis of the protein-coding content of the sequence of human cytomegalovirus strain AD169. Curr Top Microbiol Immunol 1990; 154: 125-69.
5. Griffiths PD, Emery VC. Cytomegalovirus. In: Richman DD, Whitley RJ, Hayden FG, editors. Clinical Virology. 2nd ed. Washington, DC: ASM Press; 2002. pp. 433-61.
6. Pande H, Terramani T, Churchill MA et al. Regulation of fibronectin gene expression by human cytomegalovirus. J Virol 1990; 64: 1366-9.
7. Jones TR, Wiertz EJ, Sun L et al. Human cytomegalovirus US3 impairs transport and maturation of major histocompatibility complex class I heavy chains. Proc Natl Acad Sci U S A 1996; 93: 11327-33.
8. Soderberg-Naucler C, Fish KN, Nelson JA. Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell 1997; 91: 119-26.
9. Ho M. Cytomegalovirus. Biology and Infection. 2nd ed. New York: Plenum Publishing; 1991.
10. Salzberger B, Myerson D, Boeckh M. Circulating cytomegalovirus (CMV)-infected endothelial cells in marrow transplant patients with CMV disease and CMV infection. J Infect Dis 1997; 176: 778-81.
11. Meyers JD. Prevention of cytomegalovirus infection after marrow transplantation. Rev Infect Dis 1989; 11(Suppl 7): S1691-705.
12. Bowden RA, Slichter SJ, Sayers MH et al. Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant. Blood 1991; 78: 246-50.
13. Boeckh M, Leisenring W, Riddell SR et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 2003; 101: 407-14.
14. Neiman P, Wasserman PB, Wentworth BB et al. Interstitial pneumonia and cytomegalovirus infection as complications of human marrow transplantation. Transplantation 1973; 15: 478-85.
15. Neiman PE, Reeves W, Ray G et al. A prospective analysis interstitial pneumonia and opportunistic viral infection among recipients of allogeneic bone marrow grafts. J Infect Dis 1977; 136: 754-67.
16. Meyers JD, Flournoy N, Thomas ED. Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis 1986; 153: 478-88.
17. Miller WJ, McCullough J, Balfour HH Jr. et al. Prevention of cytomegalovirus infection following bone marrow transplantation: a randomized trial of blood product screening. Bone Marrow Transplant 1991; 7: 227-34.
18. Nichols WG, Corey L, Gooley T et al. High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. J Infect Dis 2002; 185: 273-82.
19. Winston DJ, Ho WG, Lin CH et al. Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation. Ann Intern Med 1987; 106: 12-18.
20. Bowden RA, Sayers M, Flournoy N et al. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. N Engl J Med 1986; 314: 1006-10.
21. Sullivan KM, Kopecky KJ, Jocom J et al. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med 1990; 323: 705-12.
22. De Witte T, Schattenberg A, Van Dijk BA et al. Prevention of primary cytomegalovirus infection after allogeneic bone marrow transplantation by using leukocyte-poor random blood products from cytomegalovirus-unscreened blood-bank donors. Transplantation 1990; 50: 964-8.
23. Goodrich JM, Mori M, Gleaves CA et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med 1991; 325: 1601-7.
24. Goodrich JM, Bowden RA, Fisher L et al. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993; 118: 173-8.
25. Schmidt GM, Horak DA, Niland JC et al. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants: the City of Hope-Stanford-Syntex CMV Study Group. N Engl J Med 1991; 324: 1005-11.
26. Meyers JD, Reed EC, Shepp DH et al. Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. N Engl J Med 1988; 318: 70-5.
27. Einsele H, Hebart H, Kauffmann-Schneider C et al. Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection. Bone Marrow Transplant 2000; 25: 757-63.
28. Zaia JA, Schmidt GM, Chao NJ et al. Preemptive ganciclovir administration based solely on asymptomatic pulmonary cytomegalovirus infection in allogeneic bone marrow transplant recipients: long-term follow-up. Biol Blood Marrow Transplant 1995; 1: 88-93.
29. Einsele H, Ehninger G, Hebart H et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 1995; 86: 2815-20.
30. Boeckh M, Gooley TA, Myerson D et al. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 1996; 88: 4063-71.
31. Yun Z, Lewensohn-Fuchs I, Ljungman P et al. Real-time monitoring of cytomegalovirus infections after stem cell transplantation using the TaqMan polymerase chain reaction assays. Transplantation 2000; 69: 1733-6.
32. Junghanss C, Boeckh M, Carter RA et al. Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood 2002; 99: 1978-85.
33. Wingard JR, Chen DY, Burns WH et al. Cytomegalovirus infection after autologous bone marrow transplantation with comparison to infection after allogeneic bone marrow transplantation. Blood 1988; 71: 1432-7.
34. Reusser P, Fisher LD, Buckner CD et al. Cytomegalovirus infection after autologous bone marrow transplantation: occurrence of cytomegalovirus disease and effect on engraftment. Blood 1990; 75: 1888-94.
35. Boeckh M, Stevens-Ayers T, Bowden RA. Cytomegalovirus pp65 antigenemia after autologous marrow and peripheral blood stem cell transplantation. J Infect Dis 1996; 174: 907-12.
36. Hebart H, Schroder A, Loffler J et al. Cytomegalovirus monitoring by polymerase chain reaction of whole blood samples from patients undergoing autologous bone marrow or peripheral blood progenitor cell transplantation. J Infect Dis 1997; 175: 1490-3.
37. Appelbaum FR, Meyers JD, Fefer A et al. Nonbacterial nonfungal pneumonia following marrow transplantation in 100 identical twins. Transplantation 1982; 33: 265-8.
38. Meyers JD, Flournoy N, Thomas ED. Cytomegalovirus infection and specific cell-mediated immunity after marrow transplant. J Infect Dis 1980; 142: 816-24.
39. Quinnan GV Jr., Kirmani N, Rook AH et al. Cytotoxic T cells in cytomegalovirus infection: HLArestricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrowtransplant recipients. N Engl J Med 1982; 307: 7-13.
40. Rook AH, Quinnan GV, Frederick WJR. Importance of cytotoxic lymphocytes during cytomegalovirus infection in renal transplant recipients. 1984; 76: 385-92.
41. Reusser P, Riddell SR, Meyers JD et al. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 1991; 78: 1373-80.
42. Ljungman P, Perez-Bercoff L, Jonsson J et al. Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation. Haematologica 2006; 91: 78-83.
43. Hakki M, Riddell SR, Storek J et al. Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation. Blood 2003; 102: 3060-7.
44. Zaia JA, Sissons JG, Riddell S et al. Status of cytomegalovirus prevention and treatment in 2000. Hematology Am Soc Hematol Educ Program 2000: 339-55.
45. Lacey SF, Diamond DJ, Zaia JA. Assessment of cellular immunity to human cytomegalovirus in recipients of allogeneic stem cell transplants. Biol Blood Marrow Transplant 2004; 10: 433-47.
46. Sylwester AW, Mitchell BL, Edgar JB et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med 2005; 202: 673-85.
47. Cwynarski K, Ainsworth J, Cobbold M et al. Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation. Blood 2001; 97: 1232-40.
48. Gratama JW, van Esser JW, Lamers CH et al. Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8+ T lymphocytes in Tcell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection. Blood 2001; 98: 1358-64.
49. Gallez-Hawkins G, Thao L, Lacey SF et al. Cytomegalovirus immune reconstitution occurs in recipients of allogeneic hematopoietic cell transplants irrespective of detectable cytomegalovirus infection. Biol Blood Marrow Transplant 2005; 11: 890-902.
50. Lacey SF, Gallez-Hawkins G, Crooks M et al. Characterization of cytotoxic function of CMVpp65-specific CD8+ T-lymphocytes identified by HLA tetramers in recipients and donors of stemcell transplants. Transplantation 2002; 74: 722-32.
51. Carrington M, Martin MP. The impact of variation at the KIR gene cluster on human disease. Curr Top Microbiol Immunol 2006; 298: 225-57.
52. Cook M, Briggs D, Craddock C et al. Donor KIR genotype has a major influence on the rate of cytomegalovirus reactivation following T-cell replete stem cell transplantation. Blood 2006; 107: 1230-2.
53. Chen C, Busson M, Rocha V et al. Activating KIR genes are associated with CMV reactivation and survival after non-T-cell depleted HLA-identical sibling bone marrow transplantation for malignant disorders. Bone Marrow Transplant 2006; 38: 437-44.
54. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34: 1094-7.
55. Wingard JR, Mellits ED, Sostrin MB et al. Interstitial pneumonitis after allogeneic bone marrow transplantation. Nine-year experience at a single institution. Medicine (Baltimore) 1988; 67: 175-86.
56. Winston DJ, Ho WG, Champlin RE. Cytomegalovirus infections after allogeneic bone marrow transplantation. Rev Infect Dis 1990; 12(Suppl 7): S776-92.
57. Beschorner WE, Hutchins GM, Burns WH et al. Cytomegalovirus pneumonia in bone marrow transplant recipients: miliary and diffuse patterns. Am Rev Respir Dis 1980; 122: 107-14.
58. Myerson D, Hackman RC, Nelson JA et al. Widespread presence of histologically occult cytomegalovirus. Hum Pathol 1984; 15: 430-9.
59. Zaia JA. The biology of human cytomegalovirus infection after bone marrow transplantation. Int J Cell Cloning 1986; 4(Suppl 1): 135-54.
60. Zaia JA. Understanding human cytomegalovirus infection. In: Champlin RE, Gale RP, editors. New Strategies Bone Marrow Transplantation UCLA Symposia on Molecular and Cellular Biology New Series. New York: Wiley-Liss; 1990. pp. 319-34.
61. Slavin MA, Gleaves CA, Schoch HG et al. Quantification of cytomegalovirus in bronchoalveolar lavage fluid after allogeneic marrow transplantation by centrifugation culture. J Clin Microbiol 1992; 30: 2776-9.
62. McDonald GB, Sharma P, Hackman RC et al. Esophageal infections in immunosuppressed patients after marrow transplantation. Gastroenterology 1985; 88(5 Pt 1): 1111-17.
63. Page MJ, Dreese JC, Poritz LS et al. Cytomegalovirus enteritis: a highly lethal condition requiring early detection and intervention. Dis Colon Rectum 1998; 41: 619-23.
64. van Burik JA, Lawatsch EJ, DeFor TE et al. Cytomegalovirus enteritis among hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant 2001; 7: 674-9.
65. Boeckh M, Hoy C, Torok-Storb B. Occult cytomegalovirus infection of marrow stroma. Clin Infect Dis 1998; 26: 209-10.
66. Meyers JD, Thomas ED. Infection complicating bone marrow transplantation. In: Rubin RH, Young LS, editors. Clinical Approach to Infection in the Compromised Host. 2nd edn. New York: Plenum; 1981. pp. 525-56.
67. Shepp DH, Dandliker PS, de Miranda P et al. Activity of 9-[2-hydroxy-1-(hydroxymethyl)etho xymethyl]guanine in the treatment of cytomegalovirus pneumonia. Ann Intern Med 1985; 103: 368-73.
68. Winston DJ, Ho WG, Bartoni K et al. Ganciclovir therapy for cytomegalovirus infections in recipients of bone marrow transplants and other immunosuppressed patients. Rev Infect Dis 1988; 10(Suppl 3): S547-53.
69. Erice A, Jordan MC, Chace BA et al. Ganciclovir treatment of cytomegalovirus disease in transplant recipients and other immunocompromised hosts. JAMA 1987; 257: 3082-7.
70. Masur H, Lane HC, Palestine A et al. Effect of 9-(1,3-dihydroxy-2-propoxymethyl) guanine on serious cytomegalovirus disease in eight immunosuppressed homosexual men. Ann Intern Med 1986; 104: 41-4.
71. Reed EC, Dandliker PS, Meyers JD. Treatment of cytomegalovirus pneumonia with 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanin e and high-dose corticosteroids. Ann Intern Med 1986; 105: 214-15.
72. Reed EC, Bowden RA, Dandliker PS et al. Treatment of cytomegalovirus (CMV) pneumonia in bone marrow transplant (BMT) patients (PTS) with ganciclovir (GCV) and CMV immunoglobulin (CMV-IG). Blood 1987; 70: 313a.
73. Bratanow N, Ash RC, Turner P. The use of 9(1,3-dihydroxy-2-propoxymethyl) guanine (ganciclovir, DHPG) and intravenous immunoglobulin (IVIG) in the treatment of serious cytomegalovirus (CMV) infections in thirty-one allogeneic bone marrow transplant (BMT) patients. Blood 1987; 70: 302a.
74. Reed EC, Bowden RA, Dandliker PS et al. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. Ann Intern Med 1988; 109: 783-8.
75. Emanuel D, Cunningham I, Jules-Elysee K et al. Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin. Ann Intern Med 1988; 109: 777-82.
76. Schmidt GM, Kovacs A, Zaia JA et al. Ganciclovir/ immunoglobulin combination therapy for the treatment of human cytomegalovirus-associated interstitial pneumonia in bone marrow allograft recipients. Transplantation 1988; 46: 905-7.
77. Ljungman P. Cytomegalovirus infections in transplant patients. Scand J Infect Dis Suppl 1996; 100: 59-63.
78. Reed EC, Wolford JL, Kopecky KJ et al. Ganciclovir for the treatment of cytomegalovirus gastroenteritis in bone marrow transplant patients. A randomized, placebo-controlled trial. Ann Intern Med 1990; 112: 505-10.
79. Choi JH, Kim DW, Cho SG et al. Pre-emptive ganciclovir treatment can play a role in restoration of hematopoiesis after allogeneic bone marrow transplantation. Bone Marrow Transplant 1997; 19: 187-90.
80. Salzberger B, Bowden RA, Hackman RC et al. Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: risk factors and outcome. Blood 1997; 90: 2502-8.
81. Zaia JA. Prevention and management of CMVrelated problems after hematopoietic stem cell transplantation. Bone Marrow Transplant 2002; 29: 633-8.
82. Zaia JA, Molinder KM. Advances in CMV diagnostic testing and their implications for the management of CMV infection in transplant recipients. In: Singh N, Aguado JM, editors. Infectious Complications in Transplant Patients. Boston: Kluwer Academic Publishers; 2000. pp. 75-92.
83. Bacigalupo A, Tedone E, Van Lint MT et al. CMV prophylaxis with foscarnet in allogeneic bone marrow transplant recipients at high risk of developing CMV infections. Bone Marrow Transplant 1994; 13: 783-8.
84. Bacigalupo A, Bregante S, Tedone E et al. Combined foscarnet-ganciclovir treatment for cytomegalovirus infections after allogeneic hemopoietic stem cell transplantation (Hsct). Bone Marrow Transplant 1996; 18(Suppl 2): 110-24.
85. Ljungman P, Oberg G, Aschan J et al. Foscarnet for pre-emptive therapy of CMV infection detected by a leukocyte-based nested PCR in allogeneic bone marrow transplant patients. Bone Marrow Transplant 1996; 18: 565-8.
86. Nichols WG, Corey L, Gooley T et al. Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes. Blood 2001; 97: 867-74.
87. Avetisyan G, Aschan J, Hagglund H et al. Evaluation of intervention strategy based on CMVspecific immune responses after allogeneic SCT. Bone Marrow Transplant 2007; 40: 865-9.
88. Reusser P, Attenhofer R, Hebart H et al. Cytomegalovirus-specific T-cell immunity in recipients of autologous peripheral blood stem cell or bone marrow transplants. Blood 1997; 89: 3873-9.
89. Holmberg LA, Boeckh M, Hooper H et al. Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation. Blood 1999; 94: 4029-35.
90. Hebart H, Brugger W, Grigoleit U et al. Risk for cytomegalovirus disease in patients receiving polymerase chain reaction-based preemptive antiviral therapy after allogeneic stem cell transplantation depends on transplantation modality. Blood 2001; 97: 2183-5.
91. Boeckh M, Gallez-Hawkins GM, Myerson D et al. Plasma polymerase chain reaction for cytomegalovirus DNA after allogeneic marrow transplantation: comparison with polymerase chain reaction using peripheral blood leukocytes, pp65 antigenemia, and viral culture. Transplantation 1997; 64: 108-13.
92. Kroger N, Zabelina T, Kruger W et al. Patient cytomegalovirus seropositivity with or without reactivation is the most important prognostic factor for survival and treatment-related mortality in stem cell transplantation from unrelated donors using pretransplant in vivo T-cell depletion with anti-thymocyte globulin. Br J Haematol 2001; 113: 1060-71.
93. Verdonck LF, Van den Hoek MR, Rozenberg-Arska M et al. A risk-adapted approach with a short course of ganciclovir to prevent cytomegalovirus (CMV) pneumonia in CMV-seropositive recipients of allogeneic bone marrow transplants. Clin Infect Dis 1997; 24: 901-7.
94. Slavin MA, Gooley TA, Bowden RA. Prediction of cytomegalovirus pneumonia after marrow transplantation from cellular characteristics and cytomegalovirus culture of bronchoalveolar lavage fluid. Transplantation 1994; 58: 915-19.
95. Humar A, Lipton J, Welsh S et al. A randomised trial comparing cytomegalovirus antigenemia assay vs screening bronchoscopy for the early detection and prevention of disease in allogeneic bone marrow and peripheral blood stem cell transplant recipients. Bone Marrow Transplant 2001; 28: 485-90.
96. Gleaves CA, Smith TF, Shuster EA et al. Rapid detection of cytomegalovirus in MRC-5 cells inoculated with urine specimens by using lowspeed centrifugation and monoclonal antibody to an early antigen. J Clin Microbiol 1984; 19: 917-19.
97. Hebart H, Gamer D, Loeffler J et al. Evaluation of Murex CMV DNA hybrid capture assay for detection and quantitation of cytomegalovirus infection in patients following allogeneic stem cell transplantation. J Clin Microbiol 1998; 36: 1333-7.
98. Hebart H, Rudolph T, Loeffler J et al. Evaluation of the NucliSens CMV pp67 assay for detection and monitoring of human cytomegalovirus infection after allogeneic stem cell transplantation. Bone Marrow Transplant 2002; 30: 181-7.
99. Cole NL, Balfour HH Jr. In vitro susceptibility of cytomegalovirus isolates from immunocompromised patients to acyclovir and ganciclovir. Diagn Microbiol Infect Dis 1987; 6: 255-61.
100. Balfour HH Jr., Chace BA, Stapleton JT et al. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N Engl J Med 1989; 320: 1381-7.
101. Fletcher CV, Englund JA, Edelman CK et al. Pharmacologic basis for high-dose oral acyclovir prophylaxis of cytomegalovirus disease in renal allograft recipients. Antimicrob Agents Chemother 1991; 35: 938-43.
102. Boeckh M, Gooley TA, Reusser P et al. Failure of high-dose acyclovir to prevent cytomegalovirus disease after autologous marrow transplantation. J Infect Dis 1995; 172: 939-43.
103. Prentice HG, Gluckman E, Powles RL et al. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group. Lancet 1994; 343: 749-53.
104. Prentice HG, Gluckman E, Powles RL et al. Long-term survival in allogeneic bone marrow transplant recipients following acyclovir prophylaxis for CMV infection. The European Acyclovir for CMV Prophylaxis Study Group. Bone Marrow Transplant 1997; 19: 129-33.
105. Boeckh M, Gooley TA, Bowden RA. Effect of high-dose acyclovir on survival in allogeneic marrow transplant recipients who received ganciclovir at engraftment or for cytomegalovirus pp65 antigenemia. J Infect Dis 1998; 178: 1153-7.
106. Vusirikala M, Wolff SN, Stein RS et al. Valacyclovir for the prevention of cytomegalovirus infection after allogeneic stem cell transplantation: a single institution retrospective cohort analysis. Bone Marrow Transplant 2001; 28: 265-70.
107. Ljungman P, de La Camara R, Milpied N et al. Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants. Blood 2002; 99: 3050-6.
108. Reusser P, Gambertoglio JG, Lilleby K et al. Phase I-II trial of foscarnet for prevention of cytomegalovirus infection in autologous and allogeneic marrow transplant recipients. J Infect Dis 1992; 166: 473-9.
109. Boeckh M, Zaia JA, Jung D et al. A study of the pharmacokinetics, antiviral activity, and tolerability of oral ganciclovir for CMV prophylaxis in marrow transplantation. Biol Blood Marrow Transplant 1998; 4: 13-19.
110. Frenkel LM, Capparelli EV, Dankner WM et al. Oral ganciclovir in children: pharmacokinetics, safety, tolerance, and antiviral effects. The Pediatric AIDS Clinical Trials Group. J Infect Dis 2000; 182: 1616-24.
111. Ljungman P, Deliliers GL, Platzbecker U et al. Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Blood 2001; 97: 388-92.
112. Snydman DR. Historical overview of the use of cytomegalovirus hyperimmune globulin in organ transplantation. Transpl Infect Dis 2001; 3(Suppl 2): 6-13.
113. Zaia JA. Cytomegalovirus infections. In: Thomas ED, Blume KG, Forman SF, editors. Hematopoietic Cell Transplantation. 2nd edn. Oxford, England: Blackwell Science; 1998. pp. 560-83.
114. Couchoud C, Cucherat M, Haugh M et al. Cytomegalovirus prophylaxis with antiviral agents in solid organ transplantation: a meta-analysis. Transplantation 1998; 65: 641-7.
115. Zaia JA, Levin MJ, Leszczynski J et al. Cytomegalovirus immune globulin: production from selected normal donor blood. Transplantation 1979; 27: 66-7.
116. Boeckh M, Bowden RA, Storer B et al. Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2001; 7: 343-51.
117. Dykewicz CA. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis 2001; 33: 139-44.
118. Bowden RA, Fisher LD, Rogers K et al. Cytomegalovirus (CMV)-specific intravenous immunoglobulin for the prevention of primary CMV infection and disease after marrow transplant. J Infect Dis 1991; 164: 483-7.
119. Zaia JA, Gallez-Hawkins GM, Tegtmeier BR et al. Late cytomegalovirus disease in marrow transplantation is predicted by virus load in plasma. J Infect Dis 1997; 176: 782-5.
120. Nichols WG, Boeckh M, Carter RA et al. Transferred herpes simplex virus immunity after stemcell transplantation: clinical implications. J Infect Dis 2003; 187: 801-8.
121. Kraemer KG, Neiman PE, Reeves WC et al. Prophylactic adenine arabinoside following marrow transplantation. Transplant Proc 1978; 10: 237-40.
122. Meyers JD, McGuffin RW, Neiman PE et al. Toxicity and efficacy of human leukocyte interferon for treatment of cytomegalovirus pneumonia after marrow transplantation. J Infect Dis 1980; 141: 555-62.
123. Meyers JD, McGuffin RW, Bryson YJ et al. Treatment of cytomegalovirus pneumonia after marrow transplant with combined vidarabine and human leukocyte interferon. J Infect Dis 1982; 146: 80-4.
124. Wade JC, Hintz M, McGuffin RW et al. Treatment of cytomegalovirus pneumonia with high dose acyclovir. Am J Med 1982; 73: 249-56.
125. Wade JC, McGuffin RW, Springmeyer SC et al. Treatment of cytomegaloviral pneumonia with high-dose acyclovir and human leukocyte interferon. J Infect Dis 1983; 148: 557-62.
126. Meyers JD, Day LM, Lum LG et al. Recombinant leukocyte A interferon for the treatment of serious viral infections after marrow transplant: a phase I study. J Infect Dis 1983; 148: 551-6.
127. Winston DJ, Ho WG, Schroff RW et al. Safety and tolerance of recombinant leukocyte a interferon in bone marrow transplant recipients. Antimicrob Agents Chemother 1983; 23: 846-51.
128. Shepp DH, Newton BA, Meyers JD. Intravenous lymphoblastoid interferon and acyclovir for treatment of cytomegaloviral pneumonia. J Infect Dis 1984; 150: 776-7.
129. Blacklock HA, Griffiths P, Stirk P et al. Specific hyperimmune globulin for cytomegalovirus pneumonitis. Lancet 1985; 2: 152-3.
130. Reed EC, Bowden RA, Dandliker PS et al. Effi-cacy of cytomegalovirus immunoglobulin in marrow transplant recipients with cytomegalovirus pneumonia. J Infect Dis 1987; 156: 641-5.
131. Ringden O, Wilczek H, Lonnqvist et al. Foscarnet for cytomegalovirus infections. Lancet 1985; 1: 1503-4.
132. Ljungman P, Engelhard D, Link H et al. Treatment of interstitial pneumonitis due to cytomegalovirus with ganciclovir and intravenous immune globulin: experience of European Bone Marrow Transplant Group. Clin Infect Dis 1992; 14: 831-5.
133. Aschan J, Ringden O, Ljungman P et al. Foscarnet for treatment of cytomegalovirus infections in bone marrow transplant recipients. Scand J Infect Dis 1992; 24: 143-50.
134. Hebart H, Wuchter P, Loeffler J et al. Evaluation of the Murex CMV DNA Hybrid Capture assay (version 2.0) for early diagnosis of cytomegalovirus infection in recipients of an allogeneic stem cell transplant. Bone Marrow Transplant 2001; 28: 213-18.